JP2017517507A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517507A5
JP2017517507A5 JP2016568657A JP2016568657A JP2017517507A5 JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5 JP 2016568657 A JP2016568657 A JP 2016568657A JP 2016568657 A JP2016568657 A JP 2016568657A JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517507A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/031580 external-priority patent/WO2015179400A2/en
Publication of JP2017517507A publication Critical patent/JP2017517507A/ja
Publication of JP2017517507A5 publication Critical patent/JP2017517507A5/ja
Pending legal-status Critical Current

Links

JP2016568657A 2014-05-20 2015-05-19 急性骨髄性白血病を特徴付け、治療する方法 Pending JP2017517507A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462001015P 2014-05-20 2014-05-20
US62/001,015 2014-05-20
US201462011456P 2014-06-12 2014-06-12
US62/011,456 2014-06-12
US201462075715P 2014-11-05 2014-11-05
US62/075,715 2014-11-05
PCT/US2015/031580 WO2015179400A2 (en) 2014-05-20 2015-05-19 Methods for characterizing and treating acute myeloid leukemia

Publications (2)

Publication Number Publication Date
JP2017517507A JP2017517507A (ja) 2017-06-29
JP2017517507A5 true JP2017517507A5 (https=) 2018-07-05

Family

ID=54554957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568657A Pending JP2017517507A (ja) 2014-05-20 2015-05-19 急性骨髄性白血病を特徴付け、治療する方法

Country Status (13)

Country Link
US (1) US20170080102A1 (https=)
EP (1) EP3145542A4 (https=)
JP (1) JP2017517507A (https=)
KR (1) KR20170004003A (https=)
CN (1) CN106456762A (https=)
AU (1) AU2015264322A1 (https=)
BR (1) BR112016026730A2 (https=)
CA (1) CA2947602A1 (https=)
IL (1) IL248555A0 (https=)
MA (1) MA39885A (https=)
RU (1) RU2016147398A (https=)
SG (1) SG11201609357PA (https=)
WO (1) WO2015179400A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0316101A (pt) * 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
WO2017214433A1 (en) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AU2017355402A1 (en) * 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン, インコーポレイテッド 抗cd33イムノコンジュゲート投与計画
WO2019089594A1 (en) * 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
TW202003048A (zh) * 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
US20210285933A1 (en) * 2018-07-06 2021-09-16 University Of Washington High throughput drug screening of cancer stem cells
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体
WO2025265055A1 (en) * 2024-06-21 2025-12-26 The Johns Hopkins University Materials and methods for treating myeloid neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007814A (en) * 1992-06-15 1999-12-28 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof
BR0316101A (pt) * 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
WO2010126552A1 (en) * 2009-04-30 2010-11-04 Immunogen, Inc. Potent cell-binding agent drug conjugates
WO2012044696A2 (en) * 2010-09-30 2012-04-05 The Board Of Trustees Of The Leland Stanford Junior University Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
JP6049642B2 (ja) * 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
US20120282282A1 (en) * 2011-04-04 2012-11-08 Immunogen, Inc. Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates

Similar Documents

Publication Publication Date Title
JP2017517507A5 (https=)
RU2016147398A (ru) Способы оценивания и лечения острого миелоидного лейкоза
CN110177806B (zh) 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法
RU2756275C2 (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
JP6437922B2 (ja) Bcma抗原結合タンパク質
JP6877357B2 (ja) Gdf8阻害剤を用いて、強度及び機能を増加させる方法
ES3034582T3 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
ES3055227T3 (en) Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
JP5909442B2 (ja) ヒト化axl抗体
KR102007055B1 (ko) Cd27l 항원 결합 단백질
ES2647466T3 (es) Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3
KR102017070B1 (ko) 치료 펩티드
AU2017208554B2 (en) Neutralization of inhibitory pathways in lymphocytes
US12371507B2 (en) CDCP1 antibodies and antibody drug conjugates
JP6527132B2 (ja) 肝臓がんの診断及び治療のための組成物及び方法
US20140271644A1 (en) Combination/adjuvant therapy for wt-1-positive disease
JP2016539083A5 (https=)
US20190194309A1 (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
JP2012529281A5 (https=)
JP2017501137A5 (https=)
ES2728936T3 (es) Anticuerpos dirigidos contra CDH19 para melanoma
JP2015503909A5 (https=)
RS53327B (sr) Monoklonsko antitelo na cd44, za korišćenje u lečenju karcinoma skvamoznih ćelija glave i vrata
JPWO2020040245A5 (https=)
KR20220113951A (ko) 항-ror-2 항체 및 사용 방법